In the BioHarmony Drug Report Database

"Preview" Icon

Omalizumab

Xolair (omalizumab) is an antibody pharmaceutical. Omalizumab was first approved as Xolair on 2003-06-20. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma and urticaria. The pharmaceutical is active against Immunoglobulin heavy constant epsilon.

 

Trade Name

 

Xolair
 

Common Name

 

omalizumab
 

ChEMBL ID

 

CHEMBL1201589
 

Indication

 

asthma, urticaria
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Omalizumab structure rendering